Original Article

Identification and antifungal susceptibility patterns of Candida species isolated from blood cultures

Abstract

Background and Objectives: Candidemia is an important cause of healthcare-associated bloodstream infection, and changes in the distribution of Candida species may influence antifungal treatment strategies. This study aimed to determine the species distribution of yeasts isolated from blood cultures and evaluate their antifungal susceptibility profiles.
Materials and Methods: This retrospective study included 269 yeast isolates recovered from blood cultures between December 2017 and December 2021. Species identification was performed using the VITEK 2 YST system. Antifungal susceptibility testing was performed using Sensititre YeastOne for 215 (79.9%) isolates and VITEK 2 AST-YS08 for 54 (20.1%). Minimum inhibitory concentration results were interpreted according to applicable CLSI species-specific clinical breakpoints.
Results: Of the 269 isolates, 112 (41.6%) were Candida albicans and 157 (58.4%) were non-albicans Candida. The most frequent non-albicans species were C. parapsilosis (n=73, 27.1%), Nakaseomyces glabrata (C. glabrata) (n=37, 13.8%), and C. tropicalis (n=34, 12.6%). Fluconazole MIC50/MIC90 values were 0.5/256 mg/L for C. albicans, 1/16 mg/L for C. parapsilosis, 8/32 mg/L for C. glabrata, and 1/4 mg/L for C. tropicalis.
Conclusion: The predominance of non-albicans Candida, particularly C. parapsilosis, highlights the importance of continuous local surveillance. Methodological differences between commercial susceptibility testing systems should be considered when interpreting antifungal susceptibility results.

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
2. Thomas-Rüddel DO, Schlattmann P, Pletz M, Kurzai O, Bloos F. Risk factors for invasive Candida infection in critically ill patients: a systematic review and meta-analysis. Chest 2022; 161: 345-355.
3. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62: e1-e50.
4. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21: 606-625.
5. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997-2016. Open Forum Infect Dis 2019; 6(Suppl 1): S79-S94.
6. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 2014; 20 Suppl 6: 5-10.
7. Ricotta EE, Lai YL, Babiker A, Strich JR, Kadri SS, Lionakis MS, et al. Invasive candidiasis species distribution and trends, United States, 2009-2017. J Infect Dis 2021; 223: 1295-1302.
8. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol 2017; 7: 2173.
9. Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis 2015; 61(Suppl 6): S612-S617.
10. Wong KY, Gardam D, Boan P. Comparison of Vitek 2 YS08 with Sensititre YeastOne for Candida susceptibility testing. Pathology 2019; 51: 668-669.
11. Lee H, Choi SH, Oh J, Koo J, Lee HJ, Cho SI, et al. Comparison of six antifungal susceptibilities of 11 Candida species using the VITEK2 AST-YS08 card and broth microdilution method. Microbiol Spectr 2022; 10(2): e0125321.
12. Lim HJ, Shin JH, Kim MN, Yong D, Byun SA, Choi MJ, et al. Evaluation of two commercial broth microdilution methods using different interpretive criteria for the detection of molecular mechanisms of acquired azole and echinocandin resistance in four common Candida species. Antimicrob Agents Chemother 2020; 64(11): e00740-20.
13. Berkow EL, Lockhart SR, Ostrosky-Zeichner L. Antifungal susceptibility testing: current approaches. Clin Microbiol Rev 2020; 33(3): e00069-19.
14. Wiederhold NP. Antifungal susceptibility testing: a primer for clinicians. Open Forum Infect Dis 2021; 8(11): ofab444.
15. Espinel-Ingroff A. Commercial methods for antifungal susceptibility testing of yeasts: strengths and limitations as predictors of resistance. J Fungi (Basel) 2022; 8: 309.
16. CLSI (2020). Performance Standards for Antifungal Susceptibility Testing of Yeasts. 2nd ed. CLSI supplement M60.
17. CLSI (2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI standard M27.
18. Arastehfar A, Daneshnia F, Hilmioğlu-Polat S, Fang W, Yaşar M, Polat F, et al. First report of candidemia clonal outbreak caused by emerging fluconazole-resistant Candida parapsilosis isolates harboring Y132F and/or Y132F+K143R in Turkey. Antimicrob Agents Chemother 2020; 64: e01001-20.
19. Arastehfar A, Hilmioğlu-Polat S, Daneshnia F, Pan W, Hafez A, Fang W, et al. Clonal candidemia outbreak by Candida parapsilosis carrying Y132F in Turkey: evolution of a persisting challenge. Front Cell Infect Microbiol 2021; 11: 676177.
20. Ünal N, Spruijtenburg B, Arastehfar A, Gümral R, de Groot T, Meijer EFJ, et al. Multicentre study of Candida parapsilosis blood isolates in Türkiye highlights an increasing rate of fluconazole resistance and emergence of echinocandin and multidrug resistance. Mycoses 2024; 67(11): e70000.
21. Escribano P, Guinea J. Fluconazole-resistant Candida parapsilosis: a new emerging threat in the fungi arena. Front Fungal Biol 2022; 3: 1010782.
22. Díaz-García J, Gómez A, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, et al. Evidence of fluconazole-resistant Candida parapsilosis genotypes spreading across hospitals located in Madrid, Spain and harboring the Y132F ERG11p substitution. Antimicrob Agents Chemother 2022; 66: e00710-22.
23. Alcoceba E, Gómez A, Lara-Esbrí P, Oliver A, Ferre Beltrán A, Ayestarán I, et al. Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain. Clin Microbiol Infect 2022; 28: 1113-1119.
24. Kidd SE, Crawford LC, Halliday CL. Antifungal susceptibility testing and identification. Infect Dis Clin North Am 2021; 35: 313-339.
25. McCarty TP, Luethy PM, Baddley JW, Pappas PG. Clinical utility of antifungal susceptibility testing. JAC Antimicrob Resist 2022; 4(3): dlac067.
Files
IssueVol 18 No 5 (2026) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v18i5.22862
Keywords
Candidemia Microbial sensitivity tests Antifungal agents Drug resistance Fungal
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Sohrabi Molla Yousefi P. Identification and antifungal susceptibility patterns of Candida species isolated from blood cultures. Iran J Microbiol. 2026;18(5):712-717.